BTMD Stock Price, Biote Corp Quote, Chart

Market Summary

USD5.75-0.09

Delayed

-1.54%

BTMD Stock Price

View Fullscreen

BTMD RSI Chart

BTMD Valuation

Market Cap

199.1M

Price/Earnings (Trailing)

26.03

Price/Sales (Trailing)

1.06

EV/EBITDA

7.51

Price/Free Cashflow

9.82

BTMD Price/Sales (Trailing)

BTMD Profitability

Operating Margin

73.94%

EBT Margin

9.26%

Return on Equity

-17.03%

Return on Assets

4.78%

Free Cashflow Yield

10.18%

BTMD Fundamentals

BTMD Revenue

Revenue (TTM)

187.3M

Rev. Growth (Yr)

4.37%

Rev. Growth (Qtr)

2.41%

BTMD Earnings

Earnings (TTM)

7.6M

Earnings Growth (Yr)

72.89%

Earnings Growth (Qtr)

-130.54%

Breaking Down BTMD Revenue

Last 7 days

-6.0%

Last 30 days

4.2%

Last 90 days

22.9%

How does BTMD drawdown profile look like?

BTMD Financial Health

Current Ratio

4.75

Debt/Equity

-2.34

Debt/Cashflow

0.2

BTMD Investor Care

Shares Dilution (1Y)

96.88%

Diluted EPS (TTM)

0.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	187.3M	0	0	0
2023	172.7M	180.6M	184.1M	185.4M
2022	145.0M	151.6M	158.0M	165.0M
2021	122.3M	128.0M	133.7M	139.4M
2020	0	0	0	116.6M
2019	0	0	0	110.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Biote Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jul 05, 2023	conlon mary elizabeth	sold	-40,573	6.5021	-6,240	general counsel
Jun 30, 2023	conlon mary elizabeth	acquired	-	-	24,231	general counsel
Jun 30, 2023	cone stephen mark	acquired	-	-	6,058	-
Jun 30, 2023	jacoby dana lynn	acquired	-	-	6,058	-
Jun 09, 2023	roystone capital management lp	acquired	-	-	99,372	-
Apr 04, 2023	conlon mary elizabeth	sold	-64,382	5.9246	-10,867	general counsel
Mar 31, 2023	conlon mary elizabeth	acquired	-	-	39,375	general counsel
Mar 31, 2023	cone stephen mark	acquired	-	-	9,844	-
Mar 31, 2023	jacoby dana lynn	acquired	-	-	9,844	-
Feb 07, 2023	roystone capital management lp	bought	1,218,750	3.25	375,000	-

Which funds bought or sold BTMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-78,595	-	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.93	-3,221	8,161	-%
May 15, 2024	Royal Bank of Canada	reduced	-42.25	-29,000	62,000	-%
May 15, 2024	STATE STREET CORP	added	7.4	329,160	1,590,240	-%
May 15, 2024	MORGAN STANLEY	reduced	-5.11	35,511	346,667	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-43.54	-153,446	301,785	-%
May 15, 2024	BARCLAYS PLC	reduced	-23.61	-21,000	175,000	-%
May 15, 2024	325 CAPITAL LLC	unchanged	-	3,239,330	21,846,700	10.09%
May 15, 2024	B. Riley Asset Management, LLC	sold off	-100	-95,577	-	-%
May 15, 2024	SW Investment Management LLC	reduced	-25.93	-434,500	2,900,000	0.93%

Are Funds Buying or Selling BTMD?

Are funds buying BTMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BTMD

No. of Funds

Unveiling Biote Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	roystone capital management lp	6.9%	2,349,372	SC 13G/A
Feb 14, 2024	roystone capital management lp	9.0%	3,070,938	SC 13G/A
Feb 13, 2024	boston partners	2.45%	831,841	SC 13G/A
Feb 13, 2024	bandera partners llc	5.4%	1,832,732	SC 13G/A
Feb 12, 2024	lmr partners llp	0%	0	SC 13G/A
Oct 12, 2022	lmr partners llp	4.2%	397,884	SC 13G

Recent SEC filings of Biote Corp

View All Filings

Date Filed	Form Type	Document
May 10, 2024	10-Q	Quarterly Report
May 10, 2024	424B3	Prospectus Filed
May 10, 2024	424B3	Prospectus Filed
May 07, 2024	8-K	Current Report
Apr 29, 2024	8-K	Current Report
Apr 11, 2024	ARS	ARS
Apr 11, 2024	DEF 14A	DEF 14A
Apr 11, 2024	DEFA14A	DEFA14A
Apr 09, 2024	424B3	Prospectus Filed
Apr 09, 2024	424B3	Prospectus Filed

Peers (Alternatives to Biote Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	482.9B	379.5B	9.53%	9.48%	31.44	1.27	12.96%	-25.81%
CI	96.2B	206.0B	-2.11%	32.08%	24.97	0.47	12.55%	-43.95%
HCA	84.6B	66.7B	3.80%	15.55%	15.46	1.27	9.59%	-4.59%
CVS	72.4B	360.9B	-15.92%	-16.78%	9.89	0.2	9.07%	78.49%
CNC	41.7B	155.5B	8.44%	18.66%	15.24	0.27	6.34%	84.42%
DVA	12.3B	12.3B	9.53%	38.52%	15.03	0.99	5.77%	58.74%
UHS	11.9B	14.7B	11.04%	30.82%	14.63	0.81	7.99%	19.23%
MID-CAP
CHE	8.5B	2.3B	-6.47%	5.37%	30.15	3.73	5.96%	18.29%
ACHC	6.2B	3.0B	-5.49%	-7.73%	-545.12	2.06	10.92%	-104.06%
AMEH	2.3B	1.5B	9.06%	20.53%	36.62	1.57	19.34%	40.15%
AMN	2.2B	3.5B	4.01%	-38.44%	15.49	0.64	-27.67%	-62.43%
SMALL-CAP
ADUS	1.8B	1.1B	14.53%	25.72%	27.59	1.67	11.45%	30.74%
BKD	1.3B	3.0B	6.97%	85.25%	-7.66	0.44	4.98%	4.88%
BEAT	54.5M	-	-4.17%	-6.33%	-3.61	-	-	-1.05%
AMS	22.0M	21.6M	16.05%	23.93%	39.79	1.02	9.04%	-50.63%

Biote Corp News

Latest updates

Biote Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Revenue	2.4%	46,804	45,703	45,557	49,257	44,843	44,485	41,970	41,359	37,143	37,536	35,567	34,750	-	-	-
Cost Of Revenue	-	-	-	-	-	-	-	-	-	12,277	-	-	-	11,361	-	-
S&GA Expenses	-12.1%	23,010	26,190	23,791	25,760	23,085	21,758	20,818	113,425	15,103	15,953	12,311	11,327	9,463	-	-
EBITDA Margin	140.7%	0.16*	0.07*	0.08*	-0.05*	-0.12*	0.05*	-0.01*	0.04*	0.25*	0.26*	0.25*	0.26*	0.27*	0.28*	0.22*
Interest Expenses	-9.1%	2,230	2,454	2,441	2,351	2,230	1,938	1,506	678	304	313	355	302	492	-	-
Income Taxes	191.1%	2,500	-2,744	3,900	922	630	437	234	-346	64.00	77.00	67.00	78.00	64.00	-	-
Earnings Before Taxes	-135.6%	-3,324	9,334	23,516	-12,173	-20,800	13,245	728	-21,675	9,414	5,557	8,604	9,839	8,905	-	-
EBT Margin	14051.5%	0.09*	0.00*	0.02*	-0.11*	-0.17*	0.01*	-0.04*	0.01*	0.23*	0.24*	0.22*	0.23*	0.24*	0.25*	0.19*
Net Income	-130.5%	-5,810	19,023	7,530	-13,095	-21,430	1,622	15.00	-2,606	9,350	5,480	8,537	9,761	8,841	-	-
Net Income Margin	194.9%	0.04*	-0.04*	-0.14*	-0.18*	-0.13*	-0.01*	0.04*	0.08*	0.23*	0.23*	0.20*	0.15*	0.24*	0.25*	0.19*
Free Cashflow	-6.3%	6,668	7,115	-291	6,770	12,930	6,046	6,393	-28,636	6,707	9,406	6,569	8,482	7,815	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	3.1%	160	155	150	139	119	112	110	115	59.00	54.00	318	318	319	33.00
Current Assets	-6.5%	114	122	118	112	107	101	101	106	52.00	47.00	1.00	1.00	2.00	28.00
Cash Equivalents	-11.5%	79.00	89.00	66.00	68.00	88.00	79.00	77.00	83.00	28.00	27.00	0.00	0.00	21.00	17.00
Inventory	9.3%	19.00	17.00	11.00	7.00	10.00	11.00	10.00	10.00	9.00	10.00	-	-	-	4.00
Net PPE	79.9%	2.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	-	-	-	2.00
Liabilities	6.9%	205	192	201	212	203	170	180	187	49.00	50.00	22.00	25.00	39.00	50.00
Current Liabilities	8.3%	24.00	22.00	25.00	22.00	20.00	19.00	22.00	33.00	17.00	17.00	0.00	0.00	0.00	12.00
Long Term Debt	-1.3%	105	107	108	109	111	112	113	115	-	32.00	-	-	-	37.00
LT Debt, Current	0%	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	-	5.00	-	-	-	5.00
LT Debt, Non Current	-100.0%	-	107	108	109	111	112	113	115	-	32.00	-	-	-	37.00
Shareholder's Equity	-22.9%	-44.90	-36.55	-	-	-83.81	-58.27	-	-	11.00	4.00	-	5.00	5.00	0.00
Retained Earnings	-6.5%	-31.30	-29.39	-40.52	-46.39	-48.53	-44.46	-48.12	-49.14	11.00	4.00	-21.45	-24.45	-37.69	-17.05
Additional Paid-In Capital	-	-	-	-	-	-	-	-	-	0.00	-	-	-	9.00	0.00
Shares Outstanding	34.7%	35.00	26.00	30.00	21.00	18.00	8.00	8.00	8.00	-	-	-	-	-	-
Minority Interest	-32.9%	-9.50	-7.15	-10.74	-26.83	-35.27	-13.81	-22.73	-22.17	-	-	-	-	-	-
Float	-	-	-	-	169	-	-	-	8.00	-	-	-	307	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Cashflow From Operations	6.0%	7,372	6,956	160	6,775	12,992	6,051	6,393	-28,570	6,969	10,080	6,322	9,361	7,957	-	-	-
Share Based Compensation	-11.7%	1,763	1,997	2,243	2,647	2,170	2,164	746	79,270	-	-	-	-	-	-	-	-
Cashflow From Investing	-164.1%	-12,176	18,996	-484	-20,845	-380	-311	-387	-658	-482	-1,047	-1,329	-946	-485	-	-	-
Cashflow From Financing	-114.2%	-5,409	-2,525	-2,562	-5,058	-4,235	-3,976	-11,262	84,260	-5,562	-5,190	-4,686	-6,875	-3,592	1.00	250*	-
Dividend Payments	-100.0%	-	1,106	1,000	3,495	3,093	2,276	1,903	5,972	2,735	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BTMD Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue
Total revenue	$ 46,804	$ 44,843
Cost of revenue
Cost of revenue	13,367	13,877
Selling, general, and administrative	23,010	23,085
Income from operations	10,427	7,881
Other income (expense) net :
Interest expense, net	(1,660)	(1,646)
Loss from change in fair value of warrant liability		(1,618)
Loss from change in fair value of earnout liability	(12,089)	(25,410)
Other income (expense)	(2)	(7)
Total other income (expense), net	(13,751)	(28,681)
Loss before provision for income taxes	(3,324)	(20,800)
Income tax expense	2,486	630
Net loss	(5,810)	(21,430)
Less: Net loss attributable to noncontrolling interest	(3,740)	(14,625)
Net loss attributable to biote Corp. stockholders	(2,070)	(6,805)
Other comprehensive income (loss):
Foreign currency translation adjustments	(1)
Other comprehensive income (loss)	(1)
Comprehensive income (loss)	$ (5,811)	$ (21,430)
Net loss per common share
Basic	$ (0.06)	$ (0.39)
Diluted	$ (0.06)	$ (0.39)
Weighted average common shares outstanding
Basic	34,621,166	17,585,045
Diluted	34,621,166	17,585,045
Product Revenue
Revenue
Total revenue	$ 46,035	$ 44,155
Cost of revenue
Cost of revenue	12,802	13,027
Service Revenue
Revenue
Total revenue	769	688
Cost of revenue
Cost of revenue	$ 565	$ 850

BTMD Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 78,787	$ 89,002
Accounts receivable, net	8,022	6,809
Inventory, net	18,917	17,307
Other current assets	8,635	9,225
Total current assets	114,361	122,343
Property and equipment, net	2,191	1,218
Capitalized software, net	4,930	4,973
Goodwill	5,525
Intangible assets, net	6,015
Operating lease right-of-use assets	2,202	1,877
Deferred tax asset	24,884	24,884
Total assets	160,108	155,295
Current liabilities
Accounts payable	4,196	4,155
Accrued expenses	9,729	8,497
Term loan, current	6,250	6,250
Deferred revenue, current	2,876	3,002
Earnout liabilities, current	600
Operating lease liabilities, current	406	311
Total current liabilities	24,057	22,215
Term loan, net of current portion	105,270	106,630
Deferred revenue, net of current portion	1,426	1,322
Operating lease liabilities, net of current portion	1,917	1,680
TRA liability	18,894	18,894
Earnout liabilities, net of current portion	53,444	41,100
Total liabilities	205,008	191,841
Commitments and contingencies (See Note 19)
Stockholders' Deficit
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued or outstanding as of March 31, 2024 and December 31, 2023
Additional paid-in capital	0	0
Accumulated deficit	(31,303)	(29,391)
Accumulated other comprehensive loss	(14)	(12)
Treasury stock, at cost	(4,088)
biote Corp.'s stockholders' deficit	(35,399)	(29,397)
Noncontrolling interest	(9,501)	(7,149)
Total stockholders' deficit	(44,900)	(36,546)
Total liabilities and stockholders' deficit	160,108	155,295
Class A Common Stock
Stockholders' Deficit
Common stock value	3	3
Class V Common Stock
Stockholders' Deficit
Common stock value	$ 3	$ 3

About Biote Corp

biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irvine, Texas.

CEO	Ms. Teresa S. Weber
WEBSITE	https://biote.com
INDUSTRY	Healthcare Plans
EMPLOYEES	186

Biote Corp Frequently Asked Questions

What is the ticker symbol for Biote Corp? What does BTMD stand for in stocks?

BTMD is the stock ticker symbol of Biote Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biote Corp (BTMD)?

As of Fri May 17 2024, market cap of Biote Corp is 199.07 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BTMD stock?

You can check BTMD's fair value in chart for subscribers.

What is the fair value of BTMD stock?

You can check BTMD's fair value in chart for subscribers. The fair value of Biote Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Biote Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BTMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Biote Corp a good stock to buy?

The fair value guage provides a quick view whether BTMD is over valued or under valued. Whether Biote Corp is cheap or expensive depends on the assumptions which impact Biote Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BTMD.

What is Biote Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, BTMD's PE ratio (Price to Earnings) is 26.03 and Price to Sales (PS) ratio is 1.06. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BTMD PE ratio will change depending on the future growth rate expectations of investors.